US › Healthcare

Ascendis Pharma AS (ASND)

US · Healthcare · Biotechnology

$244.59+0.47%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$250.7M
Revenue YoY
+148.3%
Net profit
$639.7M
Profit YoY
+776.0%
EPS
$0.27
EPS estimate
$0.43
Net margin
255.2%

EPS came in at 0.27 against a street estimate of 0.43 — a miss of 37.2%.

Key statistics

Market cap
$15.97B
P/E
28.0
Forward P/E
15.3
P/B
28.59
Book value
$9.06
EPS (TTM)
$8.68
52-week high
$282.15
52-week low
$175.19
50-day MA
$244.62
200-day MA
$226.22
Beta
0.48

Analyst view

Analysts rate Ascendis Pharma AS a strong buy (16 buy, 0 hold, 0 sell out of 16) with an average price target of $307.36.

Shareholding

Insiders
0.77%
Institutions
101.70%

Largest institutional holders

FundStake
RA Capital Management, LLC16.75%
venBio Select Advisor LLC8.25%
Westfield Capital Management Company, L.P.7.84%
FMR Inc6.32%
Artisan Partners Limited Partnership5.26%
Franklin Resources Inc3.34%
Capital Research & Mgmt Co - Division 33.19%
Massachusetts Financial Services Company3.03%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Ascendis Pharma AS — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.